Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in miceAlexandra Schäfer, Timothy P. Sheahan, Kwon Soo Chun et al.|Science Translational Medicine|2022Cited by 83
Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infectionMeghan S. Vermillion, Danielle Porter, Eisuke Murakami et al.|Science Translational Medicine|2021Cited by 42
Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in miceAlexandra Schäfer, Timothy P. Sheahan, David R. Martinez et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 24
Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infectionJared Pitts, John P. Bilello, Darius Babusis et al.|Antiviral Research|2022Cited by 13
Pharmacokinetics and Metabolism of Broad-Spectrum Antivirals Remdesivir and Obeldesivir with a Consideration to Metabolite GS-441524: Same, Similar, or Different?Darius Babusis, Raju Subramanian, Cynthia Kim et al.|Viruses|2025Cited by 5